Literature DB >> 19429081

alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity.

Guangwei Liu1, Chunyan Zhang, Juanjuan Yin, Xin Li, Furong Cheng, Yaohua Li, Hui Yang, Kenji Uéda, Piu Chan, Shun Yu.   

Abstract

alpha-Synuclein (alpha-Syn) abnormality and mitochondrial deficiency are two major changes in the brain of patients with Parkinson's disease (PD). A link between alpha-Syn and mitochondria in PD has been demonstrated by a recent study showing that accumulation of alpha-Syn in the mitochondria from the PD-vulnerable brain regions was associated with decreased complex I activity of these mitochondria. In this study, we examined the normal expressions of alpha-Syn in mitochondria from different regions of the rat brain. We showed that alpha-Syn was highly expressed in the mitochondria in olfactory bulb, hippocampus, striatum, and thalamus, where the cytosolic alpha-Syn was also rich. However, the cerebral cortex and cerebellum were two exceptions, which contained rich cytosolic alpha-Syn but very low or even undetectable levels of mitochondrial alpha-Syn. The close quantitative association between mitochondrial and cytosolic alpha-Syn in most brain regions, suggests that the concentration of cytosolic alpha-Syn may determine the amount of alpha-Syn in mitochondria. This is partially supported by the in vitro experiment showing that incubation of alpha-Syn with endogenous alpha-Syn-undetectable cerebellar mitochondria caused a dose-dependent transport of alpha-Syn to the mitochondria. Moreover, we found that the inhibitory effect of alpha-Syn on complex I activity of mitochondrial respiratory chain was also dose-dependent. These results suggest that alpha-Syn in mitochondria is differentially expressed in different brain regions and the background levels of mitochondrial alpha-Syn may be a potential factor affecting mitochondrial function and predisposing some neurons to degeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429081     DOI: 10.1016/j.neulet.2009.02.056

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  71 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.

Authors:  Erin K Butler; Aaron Voigt; A Kathrin Lutz; Jane P Toegel; Ellen Gerhardt; Peter Karsten; Björn Falkenburger; Andrea Reinartz; Konstanze F Winklhofer; Jörg B Schulz
Journal:  PLoS Genet       Date:  2012-02-02       Impact factor: 5.917

Review 3.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

4.  Selective dopaminergic neurotoxicity of three heterocyclic amine subclasses in primary rat midbrain neurons.

Authors:  Angela Cruz-Hernandez; Zeynep Sena Agim; Paola C Montenegro; George P McCabe; Jean-Christophe Rochet; Jason R Cannon
Journal:  Neurotoxicology       Date:  2018-03       Impact factor: 4.294

Review 5.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 6.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

7.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

Authors:  Adam L Orr; Florentine U Rutaganira; Daniel de Roulet; Eric J Huang; Nicholas T Hertz; Kevan M Shokat; Ken Nakamura
Journal:  Neurochem Int       Date:  2017-04-20       Impact factor: 3.921

Review 10.  Membrane remodeling and mechanics: Experiments and simulations of α-Synuclein.

Authors:  Ana West; Benjamin E Brummel; Anthony R Braun; Elizabeth Rhoades; Jonathan N Sachs
Journal:  Biochim Biophys Acta       Date:  2016-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.